|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
GlaxoSmithKline (GSK) Invests $50 Million in Biotech Startup Venture Fund to Fatten Up Drug Pipeline
1/10/2013 8:46:32 AM
GlaxoSmithKline is looking to fatten its drug pipeline through another venture capital investment with a $50 million commitment to a California fund. The drug giant on Wednesday said it would invest in the $250 million Sanderling Biotech Venture Fund. The fund will be managed out of San Mateo, Calif. The commitment is one of several made by GSK (NYS: GSK) to several funds focused on helping emerging and early-stage companies advancing potential drug candidates. GSK Chief Executive Officer Andrew Witty's growth strategy calls for Glaxo to rely more on investments and partners in seeking new products. Melinda Stubbee, a GSK spokeswoman, confirmed the investment with Bloomberg in a phone interview. Glaxo, the only large pharmaceutical company investing in the fund, will have a seat on the limited partner advisory committee, she said. The new fund fills a geographic gap in Glaxo’s early-stage investments, which include funds on the East Coast, in Europe and in Canada, Stubbee said. It also serves to encourage innovation in an area where investments have dwindled, given risks and long-term horizons for returns. “Venture money has really dried up since the economy has suffered,” she said.
|
|
|
|
|
|
|
|
|
|
|